Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Post by Royal10on Oct 22, 2020 11:01am
186 Views
Post# 31761880

Uplisting to a US market soon!

Uplisting to a US market soon!
CZO should trade at a much higher price. The problem is the poor liquidity. News like the one we have today should attract the interest of US analysts. The only way to get more liquidity is to issue more shares, like Gilles did in 2016. Long time shareholders remember that this financing was backed by good news and propulsed the stock from around 70 cents to $2.45 in less than 3 months. This move could be repeated easely now since CZO is a more mature co today that it was four years ago. In my opinion, the Market is ready for this kind of financing. The biotech sector is very hot now as we can see with the number of new shares issued by many small canadian companies (with great success).
<< Previous
Bullboard Posts
Next >>